Equities Analysts Issue Forecasts for MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Madrigal Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings of ($9.20) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.55) per share.

Several other brokerages have also recently issued reports on MDGL. JMP Securities restated a “market outperform” rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. UBS Group raised their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. B. Riley upped their price target on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright raised their price objective on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Finally, Oppenheimer cut their price objective on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $351.67.

Madrigal Pharmaceuticals Trading Up 4.6 %

Madrigal Pharmaceuticals stock opened at $307.08 on Wednesday. The business has a 50 day moving average of $313.27 and a 200-day moving average of $272.85. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals has a 1 year low of $168.25 and a 1 year high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.94) by $2.02. The firm had revenue of $62.18 million during the quarter, compared to analyst estimates of $34.60 million. During the same period in the previous year, the company earned ($5.34) EPS.

Insider Activity at Madrigal Pharmaceuticals

In other news, General Counsel Shannon T. Kelley sold 277 shares of the firm’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $273.41, for a total value of $75,734.57. Following the completion of the sale, the general counsel now directly owns 7,705 shares in the company, valued at $2,106,624.05. This trade represents a 3.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Fred B. Craves sold 3,400 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $350.30, for a total value of $1,191,020.00. Following the transaction, the director now directly owns 14,600 shares in the company, valued at approximately $5,114,380. This trade represents a 18.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,408 shares of company stock worth $4,489,207 in the last quarter. Company insiders own 22.80% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its holdings in shares of Madrigal Pharmaceuticals by 2.1% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 1,507 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 31 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Madrigal Pharmaceuticals by 1.8% in the third quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 40 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Madrigal Pharmaceuticals by 47.6% during the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 68 shares during the last quarter. Creative Planning increased its position in shares of Madrigal Pharmaceuticals by 2.7% during the third quarter. Creative Planning now owns 3,299 shares of the biopharmaceutical company’s stock worth $700,000 after acquiring an additional 87 shares in the last quarter. Finally, Verity Asset Management Inc. raised its holdings in shares of Madrigal Pharmaceuticals by 7.4% in the 3rd quarter. Verity Asset Management Inc. now owns 1,466 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 101 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.